The Nigerian Business Where the Chairs Never Empty

Walk into a dialysis unit in Lagos at six in the morning and the first thing you notice is that nobody is waiting to be seen. They are already seated. Arm out. Machine primed. Some of them have been coming to the same chair, in the same building, since before the current government took office.

That is the sound the health investors of this country have started listening for.

For two decades the Nigerian health story was told as a failure. Hospitals collapsed, doctors left, and the money followed the patients — an estimated one to two billion dollars a year abroad for treatment, on industry estimates. This year a new version of the story appeared, and it is being written not in the teaching hospitals but in single-purpose units for kidneys, hearts, fertility and cancer.

Dr. Patrick Nwachi, consultant, family physician and lifestyle medicine special, who is also the head, general outpatient and Loveworld medical centre, LMC spoke to LN247’s Yemisi Lanre Idowu. He said ”

The dialysis chair is where that shift is clearest, because the arithmetic is unusually honest.

The mathematics of a recurring patient

A standard haemodialysis patient needs the machine two or three times a week, roughly four hours a session, indefinitely — unless a transplant arrives, which for most Nigerians it does not.

The costs are documented. A 2022 peer-reviewed review of Nigerian dialysis put the average session at around ₦40,000, roughly US$96 at the time, and noted prices climbing sharply in the private sector. Recent reporting around World Kidney Day placed the range between ₦50,000 and ₦80,000 a session, with a kidney transplant quoted north of ₦25 million. On the other side of the counter, a 2023 Nigerian cost-analysis study found the provider’s variable cost per session at about US$103, and an annualised variable cost per patient near US$16,100.

Which produces the number that explains the building boom. A patient on three sessions a week is not a customer. He is an annuity.

Add the state dialysis subsidy — which in participating facilities has pulled the out-of-pocket cost down from around ₦50,000 a session to as low as ₦12,000 in some programmes — and you get the rarest thing in Nigerian business: a demand curve nobody has to advertise into existence. End-stage kidney disease does not respond to a downturn, a border closure, or a competitor’s campaign.

So when a Lagos hospital group’s chief executive says on our On The Front Burner programme that he would rather fund a dialysis unit than a 300-bed hospital, he is not being modest. He is being accurate. Machines, chairs, a nurse, and — the part everyone forgets — clean, correctly treated water. That is the whole enterprise.

Why it is not the goldmine it looks like

Then the floor arrives.

Dialysis is one of the most import-dependent services in medicine. The machine, the dialyser, the concentrates, the membranes, the fistula needles — almost none of it is made here. Which means the cost base is priced in dollars while the revenue is collected in naira, from a family that is often selling land to pay for the third month.

And when the naira moves, the margin does not flex. It simply disappears.

There is a second fragility the investors do not put in the pitch deck. A dialysis unit fails as quietly as it opens. One water-treatment fault, one batch of contaminated concentrate, one engineer who cannot land in this country for six weeks because the machine needs a part that only exists in Dubai — and the chairs go empty. Every serious operator we spoke to on this programme named the biomedical engineer as the actual scarce asset in Nigerian healthcare, ahead of the doctor.

Meanwhile, the other two hundred million

The investment story is real. It is also narrow, and it deserves a second number beside it.

The National Health Insurance Authority reports enrolment crossing 22 million people in early 2026, up from about 16 million in 2023 — roughly 10% of the population, with a target of 30 million this year. Independent academic work uses a stricter definition and puts formal insurance access nearer 5–7%.

Those two figures are not a contradiction; they are a warning about definitions. Enrolment is a card issued. Utilisation is a person who walks into a facility, is treated, and does not pay cash at the desk. HMOs have complained for years that approved capitation rates barely cover the cost of the drugs. Between a card and a chair there is a whole country.

Which brings us back to the question we asked the room, and the answer that did not come.

The part still in the drawer

Every operator on our panel could name what they have built. Not one of them, when asked, said the word published.

Mortality rates. Catheter-related bloodstream infection rates. Machine downtime. Peritonitis in peritoneal dialysis. Complaints log. In most of this country’s private health system these figures are not collected, and if collected, not released. Not because the hospitals are unusually bad — because nobody has ever required them to be measurable.

That is the actual bottleneck in Nigerian healthcare, and it is not money, not machines, and not even the twenty thousand-odd health professionals who left in a year. It is accountability. An investor can buy a scanner in ninety days. A country buys trust one published number at a time.

The chairs at six in the morning are real, and they are full, and they are good news. They are also the first honest evidence in a long time that Nigerian health money is being spent inside Nigeria.

Let the hospitals make the most of it. Then let them tell us what happened.

The line that protects us :

Enrolment is not treatment, and a fall in spending is not a cure. Insurance figures measure cards issued; independent estimates measure people with real access. And the collapse in Nigeria's measured outbound medical spending in the first half of 2025 owed much to the scarcity of dollars, not only to better hospitals at home.